Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.22 Average PT from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been assigned a consensus rating of “Buy” from the eight ratings firms that are covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $6.38.

Several brokerages have recently commented on TSHA. Piper Sandler lowered their target price on shares of Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating on the stock in a report on Monday, July 1st. Needham & Company LLC dropped their price objective on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a report on Monday, August 12th. Chardan Capital reissued a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, August 13th. BMO Capital Markets began coverage on Taysha Gene Therapies in a research note on Thursday, June 27th. They issued an “outperform” rating and a $5.00 price target for the company. Finally, Canaccord Genuity Group reduced their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA opened at $2.03 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22. The firm has a market cap of $379.65 million, a price-to-earnings ratio of -4.14 and a beta of 0.41. The stock’s fifty day moving average price is $2.20 and its two-hundred day moving average price is $2.59. Taysha Gene Therapies has a one year low of $1.27 and a one year high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. The business had revenue of $1.11 million for the quarter, compared to the consensus estimate of $3.62 million. During the same period in the prior year, the company posted ($0.38) earnings per share. On average, equities analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Transactions at Taysha Gene Therapies

In related news, major shareholder Paul B. Manning purchased 1,333,333 shares of the firm’s stock in a transaction that occurred on Thursday, June 27th. The shares were bought at an average cost of $2.25 per share, with a total value of $2,999,999.25. Following the acquisition, the insider now owns 1,333,333 shares of the company’s stock, valued at approximately $2,999,999.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently bought and sold shares of TSHA. China Universal Asset Management Co. Ltd. boosted its stake in shares of Taysha Gene Therapies by 66.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company’s stock valued at $103,000 after purchasing an additional 14,286 shares in the last quarter. Victory Capital Management Inc. acquired a new position in Taysha Gene Therapies in the 4th quarter valued at approximately $28,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Taysha Gene Therapies during the fourth quarter valued at $31,000. Principal Financial Group Inc. acquired a new position in shares of Taysha Gene Therapies during the second quarter worth $48,000. Finally, Chicago Partners Investment Group LLC lifted its holdings in shares of Taysha Gene Therapies by 21.4% during the fourth quarter. Chicago Partners Investment Group LLC now owns 134,851 shares of the company’s stock worth $239,000 after purchasing an additional 23,740 shares during the period. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.